Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD"
Clinical and Molecular Hepatology · 05.11.2026
DOI: 10.3350/cmh.2026.0471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 05.11.2026. Verfasst von Moon Haeng Hur und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine. yoonjun@snu.ac.kr.
Zitieren
APA
Hur, M. H., Shin, H., & Kim, Y. J. (2026). Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD". Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0471
Vancouver
Hur MH, Shin H, Kim YJ. Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD". Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0471
BibTeX
@article{Hur2026,
author = {Hur, Moon Haeng and Shin, Hyunjae and Kim, Yoon Jun},
title = {Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD"},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0471}
}
EUVIMED